QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.45 (-8.81%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.45 (-8.81%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.45 (-8.81%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
QQQ   287.64 (-1.68%)
AAPL   146.63 (-0.80%)
MSFT   250.20 (-1.89%)
META   122.43 (-0.86%)
GOOGL   99.48 (-0.96%)
AMZN   91.01 (-3.31%)
TSLA   182.45 (-6.37%)
NVDA   166.10 (-1.58%)
NIO   12.80 (-2.51%)
BABA   90.52 (+0.51%)
AMD   73.62 (-1.81%)
T   18.75 (-1.42%)
MU   54.04 (-1.17%)
CGC   4.32 (+0.70%)
F   13.38 (-3.46%)
GE   84.66 (-2.56%)
DIS   95.93 (-3.52%)
AMC   7.45 (-8.81%)
PYPL   73.62 (-1.39%)
PFE   50.73 (-0.35%)
NFLX   312.59 (-2.44%)
NASDAQ:NYMX

Nymox Pharmaceutical - NYMX Stock Forecast, Price & News

$0.41
+0.13 (+45.68%)
(As of 12/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.28
▼
$0.53
50-Day Range
$0.29
▼
$0.44
52-Week Range
$0.19
▼
$2.10
Volume
4.35 million shs
Average Volume
247,135 shs
Market Capitalization
$37.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NYMX stock logo

About Nymox Pharmaceutical (NASDAQ:NYMX) Stock

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.

Receive NYMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

NYMX Stock News Headlines

December 5, 2022 | finance.yahoo.com
NYMOX Announces New Marketing Submission for NYMOZARFEX™ for BPH
December 1, 2022 | americanbankingnews.com
StockNews.com Initiates Coverage on Nymox Pharmaceutical (NASDAQ:NYMX)
September 27, 2022 | finance.yahoo.com
A Nymox Pharmaceutical Corporation (NASDAQ:NYMX) insider increased their holdings by 32% last year
August 17, 2022 | nasdaq.com
We Think Nymox Pharmaceutical (NASDAQ:NYMX) Needs To Drive Business Growth Carefully
July 15, 2022 | msn.com
U.S. shares higher at close of trade; Dow Jones Industrial Average up 2.15%
July 15, 2022 | finance.yahoo.com
NYMOX Updates Shareholders
July 14, 2022 | finance.yahoo.com
NYMOX Receives Deficiency Letter from NASDAQ
May 23, 2022 | marketwatch.com
Nymox Pharmaceutical Down 64% on FDA Refusal to File Letter
May 23, 2022 | seekingalpha.com
NYMOX down 46% on Refuse to File letter from FDA for fexapotide for enlarged prostate
May 23, 2022 | marketwatch.com
Nymox Application for Fexapotide Triflutate Rejected by FDA >NYMX
May 23, 2022 | benzinga.com
Why Nymox Pharma Shares Sinking to 52-Week Low?
May 9, 2022 | uk.investing.com
Executives Buy Around $5M Of 4 Penny Stocks
May 6, 2022 | nasdaq.com
Friday 5/6 Insider Buying Report: ALGN, NYMX
April 4, 2022 | finance.yahoo.com
Nymox Announces Closing of $6.4 Million Financing
April 3, 2022 | finance.yahoo.com
A Nymox Pharmaceutical Corporation (NASDAQ:NYMX) insider increased their holdings by 1.1% last year
March 18, 2022 | msn.com
Here's Why Nymox Pharmaceuticals Shares Are Moving
March 18, 2022 | baystreet.ca
Nymox Direct Offering
March 18, 2022 | seekingalpha.com
Nymox Pharmaceutical announces $5M registered direct offering
March 18, 2022 | finance.yahoo.com
Nymox Announces $5 Million Registered Direct Offering
March 3, 2022 | marketwatch.com
Nymox Seeks FDA OK for Enlarged Prostate Treatment >NYMX
March 3, 2022 | seekingalpha.com
Nymox stock rises 8% as it files for FDA approval of drug treating enlarged prostate
March 3, 2022 | finance.yahoo.com
NYMOX Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate
January 3, 2022 | nasdaq.com
Insiders at Nymox Pharmaceutical Corporation (NASDAQ:NYMX) recouped some losses this week after buying this year, still down US$31k
December 31, 2021 | nasdaq.com
Nymox Pharmaceutical Corp Shares Near 52-Week Low - Market Mover
December 13, 2021 | finance.yahoo.com
Nymox Shareholder Update
See More Headlines
Receive NYMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

NYMX Company Calendar

Last Earnings
11/14/2014
Today
12/05/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/29/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NYMX
CUSIP
N/A
CIK
1018735
Web
www.nymox.com
Phone
(800) 936-9669
Fax
514-332-2227
Employees
3
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-12,540,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-2,902.43%
Return on Assets
-312.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.24
Quick Ratio
1.22

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.01) per share
Price / Book
-41.46

Miscellaneous

Outstanding Shares
90,515,000
Free Float
41,637,000
Market Cap
$37.53 million
Optionable
Optionable
Beta
0.67

Key Executives

  • Dr. Paul Averback DABP (Age 71)
    M.D., Founder, Chairman, CEO & Pres
    Comp: $750k
  • Mr. Randall J. Lanham Esq. (Age 58)
    J.D., Gen. Counsel, Sec., COO & Director
    Comp: $435.29k
  • Ms. Lin Dodd
    QA and Compliance Mang.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













NYMX Stock - Frequently Asked Questions

How have NYMX shares performed in 2022?

Nymox Pharmaceutical's stock was trading at $1.30 at the beginning of the year. Since then, NYMX shares have decreased by 68.1% and is now trading at $0.4146.
View the best growth stocks for 2022 here.

When is Nymox Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our NYMX earnings forecast.

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Co. (NASDAQ:NYMX) announced its quarterly earnings results on Friday, November, 14th. The biopharmaceutical company reported ($0.02) EPS for the quarter. The biopharmaceutical company had revenue of $0.08 million for the quarter.

What other stocks do shareholders of Nymox Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and CTI BioPharma (CTIC).

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

Who are Nymox Pharmaceutical's major shareholders?

Nymox Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional investors include Group One Trading L.P. (0.00%).
View institutional ownership trends.

How do I buy shares of Nymox Pharmaceutical?

Shares of NYMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nymox Pharmaceutical's stock price today?

One share of NYMX stock can currently be purchased for approximately $0.41.

How much money does Nymox Pharmaceutical make?

Nymox Pharmaceutical (NASDAQ:NYMX) has a market capitalization of $37.53 million. The biopharmaceutical company earns $-12,540,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2. The official website for the company is www.nymox.com. The biopharmaceutical company can be reached via phone at (800) 936-9669, via email at info@nymox.com, or via fax at 514-332-2227.

This page (NASDAQ:NYMX) was last updated on 12/5/2022 by MarketBeat.com Staff